Trial Profile
A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 May 2019
Price :
$35
*
At a glance
- Drugs Camptothecin (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Cerulean Pharma
- 03 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jul 2014 Planned End Date changed from 1 Feb 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 20 Sep 2013 Planned End Date changed from 1 Apr 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.